Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. (Olin Bio) has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1]. Company Overview - Olin Bio is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines. The company's strategic focus is on "super bacteria vaccines" and "adult vaccines," addressing significant unmet medical needs [4]. - Unlike many biotechnology companies that have yet to generate revenue, Olin Bio has a mature and robust commercialization platform, having successfully commercialized three products: adsorbed tetanus vaccine, Haemophilus influenzae type b (Hib) conjugate vaccine, and A/C group meningococcal polysaccharide conjugate vaccine [4][5]. - The company holds a leading market position in China for its adsorbed tetanus vaccine, with a market share exceeding 80% from 2022 to 2024 [4]. Product Pipeline - Olin Bio possesses the most comprehensive pipeline targeting "super bacteria" vaccines globally. The company is strategically developing innovative candidate vaccines against five pathogens, including: - Recombinant Staphylococcus aureus vaccine targeting Staphylococcus aureus, listed as a "high priority" by the WHO [5]. - Oral recombinant Helicobacter pylori vaccine [5]. - Recombinant Pseudomonas aeruginosa vaccine [5]. - Recombinant Acinetobacter baumannii protein vaccine [5]. - Group A Streptococcus vaccine [5]. - The company is also exploring the development of combination vaccines targeting multiple super bacteria to provide broad protection against antibiotic-resistant infections [5]. Financial Performance - Revenue for Olin Bio was approximately RMB 547 million in 2022, projected to be RMB 494 million in 2023, and expected to rise to RMB 586 million in 2024. For the first half of 2024 and 2025, revenues are estimated at RMB 225 million and RMB 305 million, respectively [6]. - The company reported profits of RMB 26.58 million in 2022, with a decline to RMB 11.44 million in 2023, and a projected profit of RMB 15.72 million in 2024. A loss of RMB 30.72 million is anticipated for the first half of 2024, with a recovery to RMB 13.23 million in the first half of 2025 [7][8]. Industry Overview - The global vaccine market (excluding COVID-19 vaccines) is projected to grow from USD 52.9 billion in 2019 to USD 73.8 billion by 2024, with a compound annual growth rate (CAGR) of 6.9%. By 2035, the market is expected to reach USD 149.5 billion, with a CAGR of 6.6% from 2024 to 2035 [9]. - In China, the vaccine market (excluding COVID-19 vaccines) is expected to grow from RMB 42.5 billion in 2019 to RMB 102 billion by 2024, with a CAGR of 19.1%. By 2035, the market is projected to reach RMB 382.5 billion, with a CAGR of 12.8% from 2024 to 2035 [11]. - The tetanus vaccine market in China has seen rapid growth, increasing from RMB 200 million in 2019 to RMB 800 million by 2024, with a CAGR of 40.2% [13].

Company Overview - 欧林生物 is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines, particularly in the areas of "superbug vaccines" and "adult vaccines" [2][3] - Unlike many biotechnology companies that have yet to generate revenue, 欧林生物 has a mature commercialization platform with three products already commercialized: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] Market Position - The company's Tetanus Toxoid Vaccine holds a leading market position in China, with a market share exceeding 80% from 2022 to 2024 [2] - 欧林生物 possesses the most comprehensive pipeline targeting "superbugs" globally, addressing significant public health challenges due to antibiotic resistance [2][3] Product Pipeline - The company is developing a 1.1 class innovative superbug candidate vaccine targeting five pathogens, including: - Recombinant Staphylococcus aureus Vaccine (rFSAV) - Oral Recombinant Helicobacter pylori Vaccine (rHPV) - Recombinant Pseudomonas aeruginosa Vaccine (rFPAV) - Recombinant Acinetobacter baumannii Protein Vaccine (rABV) - Group A Streptococcus Vaccine (GAS Vaccine) [2] Financial Performance - Revenue for 欧林生物 is projected as follows: - 2022: approximately 547 million RMB - 2023: approximately 494 million RMB - 2024: approximately 586 million RMB - 2024 (first half): approximately 225 million RMB - 2025 (first half): approximately 305 million RMB [4][6] - Profit figures are as follows: - 2022: approximately 26.58 million RMB - 2023: approximately 11.44 million RMB - 2024: approximately 15.72 million RMB - 2024 (first half): approximately -30.72 million RMB - 2025 (first half): approximately 13.23 million RMB [5][6] Industry Overview - The global vaccine market (excluding COVID-19 vaccines) is expected to grow from 52.9 billion USD in 2019 to 73.8 billion USD by 2024, with a CAGR of 6.9% [8] - The Chinese vaccine market (excluding COVID-19 vaccines) is projected to grow from 42.5 billion RMB in 2019 to 102 billion RMB by 2024, with a CAGR of 19.1% [8] - The Tetanus vaccine market in China is experiencing rapid growth, expected to increase from 200 million RMB in 2019 to 800 million RMB by 2024, with a CAGR of 40.2% [10]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securiti ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 27.72 CNY, compared to the current stock price of 23.52 CNY [4]. Core Insights - The company reported a significant revenue increase of 31.11% year-on-year, reaching 507 million CNY in the first three quarters of 2025, with a remarkable net profit growth of 1079.36% to 47 million CNY [1]. - The company is leading globally in the clinical progress of its recombinant Staphylococcus aureus vaccine, with the Phase III clinical trial expected to unblind in the first half of 2026 [3]. - The company has optimized its expense ratio, resulting in a notable improvement in profitability, with a net profit margin increase of 9.32 percentage points to 9.30% [2]. Financial Performance - In Q3 2025, the company achieved a revenue of 201 million CNY, a year-on-year increase of 25.38%, and a net profit of 34 million CNY, up 7.22% [1]. - The gross profit margin for the first three quarters of 2025 was 93.10%, with a slight year-on-year decrease of 1.62 percentage points, while the expense ratio decreased by 13.08 percentage points to 79.30% [2]. - The company’s operating cash flow turned positive, reaching 33 million CNY in the first three quarters of 2025, compared to a negative cash flow of 6.2 million CNY in the same period of 2024 [1]. Research and Development - The company invested 143 million CNY in R&D during the first three quarters of 2025, accounting for 28.19% of its revenue, focusing on vaccines for "superbugs" and "adult vaccines" [4]. - The company is advancing multiple innovative vaccine pipelines, including a recombinant Helicobacter pylori vaccine and a recombinant Pseudomonas aeruginosa vaccine, among others [7]. Future Projections - Revenue growth is projected at 23.8%, 18.7%, and 15.2% for 2025, 2026, and 2027 respectively, with net profit growth expected at 224.7%, 20.1%, and 19.1% for the same years [7].

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., is focusing on enhancing its market position through medical education and product promotion while advancing its vaccine research and clinical trials for Staphylococcus aureus and influenza vaccines [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17% [1]. - The net profit attributable to shareholders was 13.2 million yuan, with a net profit of 7.72 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. R&D Pipeline - The company is focusing on two strategic directions: "super bacteria" vaccines and "adult vaccines," continuously enriching its pipeline and enhancing innovation capabilities [2]. - The company is researching four "super bacteria" vaccines, including recombinant Staphylococcus aureus vaccine, oral recombinant Helicobacter pylori vaccine, recombinant Pseudomonas aeruginosa vaccine, and recombinant Acinetobacter baumannii protein vaccine, all classified as global Class 1 new drugs [2]. Clinical Trials - The recombinant Staphylococcus aureus vaccine has completed Phase I and II clinical trials, with Phase III trials currently ongoing and leading globally [2]. - The vaccine aims to prevent Staphylococcus aureus infections post-surgery, with no similar products available globally, indicating a broad application potential in hospital infection prevention [3]. - The company’s Helicobacter pylori vaccine received Phase I clinical trial approval in Australia in 2024, and further optimization of the oral formulation is underway for future domestic clinical trial applications [3]. Technological Advancements - The company is expanding its technological platforms and has made significant progress in the field of viral vaccines, having initiated Phase I clinical trials for trivalent and quadrivalent influenza virus split vaccines in the first half of 2025 [3].

Core Viewpoint - The company plans to acquire a total of 15% equity in its subsidiary, XinNuoMing Bio, from minority shareholders through a public transfer at a price not exceeding RMB 45 million, enhancing control and management efficiency [1][2]. Group 1: Acquisition Details - The company intends to purchase 8.11% of XinNuoMing Bio from Fund No. 1 and 6.89% from JingChuang Fund [1]. - The acquisition will increase the company's stake in XinNuoMing Bio from 84.13% to 99.13% post-transaction [1][2]. Group 2: Strategic Implications - The acquisition is expected to improve the company's control over its subsidiary and enhance overall strategic synergy and resource integration [2]. - The transaction will not change the scope of consolidation and will not adversely affect the company's financial status or operating results [2]. Group 3: Business Focus and R&D - The company specializes in the research, production, and sales of human vaccines, with a strong focus on developing vaccines for "super bacteria" and "adult vaccines" [2][3]. - The company is advancing four global Class 1 new drug projects related to the World Health Organization's list of the 12 most dangerous antibiotic-resistant bacteria [3]. Group 4: Financial Activities - The company previously announced plans to issue A-shares to specific investors, aiming to raise RMB 125 million for vaccine R&D and production base upgrades [3]. - However, the company has decided to terminate this share issuance due to market conditions and other factors, ensuring that daily operations remain unaffected [4].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. plans to issue RMB ordinary shares (A shares) to specific investors to raise a total of RMB 125.2929 million for the technical transformation project of its vaccine research and production base, enhancing its capital strength and profitability [1][2][6]. Group 1: Background and Purpose of the Issuance - The global pharmaceutical market is experiencing growth, with 2023 drug spending estimated at approximately USD 1.6 trillion, and expected to reach about USD 2.2 trillion by 2028, driven by increased drug usage and new product launches [2]. - In China, the pharmaceutical manufacturing industry achieved revenue of RMB 252.057 billion in 2023, with a projected market size of RMB 299.11 billion by 2030, reflecting a compound annual growth rate of 9.6% from 2020 to 2025 [3][4]. - The vaccine industry is a strategic focus for China's biopharmaceutical sector, supported by various government policies aimed at promoting high-quality development in disease prevention and control [5][6]. Group 2: Use of Proceeds - The funds raised will be used for the technical transformation of production lines that are currently outdated, aiming to improve production efficiency and reduce operational costs through automation and smart manufacturing upgrades [6][7]. - The company has established a dual-driven product development strategy focusing on upgrading traditional vaccines and developing innovative vaccines, particularly targeting "super bacteria" and adult vaccines [7][8]. Group 3: Financial Impact and Measures - The issuance is expected to enhance the company's production capacity and financial strength, optimizing its capital structure and reducing financial risks, thereby improving long-term profitability [6][8]. - The company has committed to measures to mitigate the dilution of immediate returns for existing shareholders, including ongoing product development and market expansion efforts [21][24]. Group 4: Compliance and Fairness of the Issuance - The issuance process has been authorized by the company's annual general meetings and complies with relevant legal regulations, ensuring fairness and protecting the interests of all shareholders [16][17]. - The selection of specific investors for the issuance adheres to regulatory requirements, ensuring that the chosen investors possess adequate risk recognition and financial capability [10][11].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and clinical trial progress [1][2]. Core Insights - The company reported a revenue of 589 million yuan in 2024, representing a year-on-year increase of 18.69%, and a net profit of 21 million yuan, also up by 18.24% [1][2]. - The first quarter of 2025 saw a revenue of 87 million yuan, a 23.58% increase year-on-year, although it reported a net loss of 7 million yuan, which is a 72.79% improvement compared to the previous year [1][2]. - The company is actively advancing its clinical trials for the recombinant pneumococcal vaccine, with over 5,600 participants enrolled as of March 2025, and expects to complete enrollment in the first half of 2025 [2]. Financial Performance Summary - In 2024, the company achieved total revenue of 589 million yuan, with a breakdown showing the tetanus vaccine revenue at 536 million yuan (up 15.73% year-on-year) and the meningococcal vaccine revenue at 26 million yuan (up 580.49% year-on-year) [2]. - The gross margin for the first quarter of 2025 improved by 1 percentage point to 93.43%, while management and R&D expense ratios decreased significantly [2]. - Revenue projections for 2025 to 2027 are estimated at 677 million yuan, 773 million yuan, and 869 million yuan, with corresponding net profits of 23 million yuan, 43 million yuan, and 60 million yuan [2][4]. Clinical Development Pipeline - The company is progressing with its pipeline of vaccines targeting superbugs, including the Helicobacter pylori vaccine, Pseudomonas aeruginosa vaccine, and Acinetobacter baumannii vaccine [2]. - The Helicobacter pylori vaccine has received Phase I clinical trial approval in Australia, and the company is optimizing the oral formulation for future domestic clinical trial applications [2]. Valuation Metrics - The projected P/E ratios for 2025, 2026, and 2027 are approximately 276, 148, and 105, respectively, indicating a high valuation relative to earnings [3][4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and clinical trial progress [1][2]. Core Insights - The company reported a revenue of 589 million yuan in 2024, representing a year-on-year increase of 18.69%, and a net profit of 21 million yuan, also up by 18.24% [1][2]. - The company is experiencing strong growth in its Tetanus vaccine segment, with a revenue of 536 million yuan in 2024, an increase of 15.73% year-on-year [2]. - The company is actively advancing its clinical trials for the recombinant Staphylococcus aureus vaccine, with over 5,600 participants enrolled as of March 2025, and expects to complete enrollment in the first half of 2025 [2]. Financial Performance Summary - In 2024, the company achieved total revenue of 589 million yuan, with a year-on-year growth rate of 18.69% [4]. - The net profit attributable to the parent company for 2024 was 21 million yuan, reflecting an 18.24% increase year-on-year [4]. - The gross profit margin for 2024 was reported at 94.4%, indicating strong profitability [4]. - The company forecasts revenues of 677 million yuan, 773 million yuan, and 869 million yuan for 2025, 2026, and 2027 respectively, with corresponding year-on-year growth rates of approximately 15%, 14%, and 13% [2][4]. Product and Market Analysis - The company’s product portfolio includes the Tetanus vaccine, which has shown consistent growth, and the newly developed Staphylococcus aureus vaccine, which is in advanced clinical trials [2]. - The company also has a pipeline of vaccines targeting superbugs, including Helicobacter pylori, Pseudomonas aeruginosa, and Acinetobacter baumannii, indicating a robust research and development strategy [2]. Earnings Forecast - The projected net profits for 2025, 2026, and 2027 are 23 million yuan, 43 million yuan, and 60 million yuan respectively, with growth rates of approximately 10%, 86%, and 40.8% [2][4]. - The earnings per share (EPS) are expected to increase from 0.06 yuan in 2025 to 0.15 yuan in 2027 [4][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 276.02 in 2025 to 105.30 in 2027, indicating improving valuation as earnings grow [4][6]. - The price-to-book (P/B) ratio is expected to decline from 75.93 in 2025 to 47.77 in 2027, reflecting a strengthening financial position [6].